0001439222-24-000052.txt : 20240305 0001439222-24-000052.hdr.sgml : 20240305 20240305161808 ACCESSION NUMBER: 0001439222-24-000052 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jones Cecilia CENTRAL INDEX KEY: 0001840056 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 24720672 MAIL ADDRESS: STREET 1: C/O LOGICBIO THERAPEUTICS, INC. STREET 2: 65 HAYDEN AVENUE, 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20080703 4 1 wk-form4_1709673462.xml FORM 4 X0508 4 2024-03-01 0 0001439222 AGIOS PHARMACEUTICALS, INC. AGIO 0001840056 Jones Cecilia C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Financial Officer 1 Common stock 2024-03-01 4 M 0 2000 0 A 15512 D Common stock 2024-03-05 4 S 0 672 32.57 D 14840 D Restricted stock units 2024-03-01 4 A 0 17000 0 A Common stock 17000 17000 D Stock options (right to buy) 32.27 2024-03-01 4 A 0 60000 0 A 2034-03-01 Common stock 60000 60000 D Restricted stock units 2024-03-01 4 M 0 2000 0 D Common stock 2000 4000 D Includes 942 shares purchased through the Company's employee stock purchase plan. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter. The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. /s/ William Cook, as attorney-in-fact for Cecilia Jones 2024-03-05